NuCana (NCNA) Short-Term Debt repayments (2019 - 2021)
NuCana's (NCNA) quarterly Short-Term Debt repayments came in at -$99752.8 in Q4 2021, down 2.09% year-on-year from -$101879.1 in Q4 2020, and up 2.22% quarter-over-quarter from -$102015.2 in Q3 2021.
NuCana (NCNA) Short-Term Debt repayments (2019 - 2021) Analysis & Trends
NuCana has disclosed Short-Term Debt repayments across 3 years of filings, most recently posting -$99752.8 for Q4 2021.
- Short-Term Debt repayments for Q4 2021 came in at -$99752.8, down 2.09% year-over-year; the trailing twelve-month figure through Dec 2021 was -$396269.0 (down 22.7% YoY), and the FY2024 annual result was -$285055.4, up 15.12% from the prior year.
- Short-Term Debt repayments came in at -$99752.8 for Q4 2021 at NuCana, up from -$102015.2 in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of -$62895.9 in Q3 2019 to a low of -$102015.2 in Q3 2021.
- The 3-year median for Short-Term Debt repayments is -$97250.5 (2020), against an average of -$87456.2.
- Across the five-year window, Short-Term Debt repayments sank 53.89% in 2020 and declined 2.09% in 2021, its largest moves.
- NuCana's Short-Term Debt repayments stood at -$65572.0 in 2019, then tumbled by 49.02% to -$97713.4 in 2020, then fell by 2.09% to -$99752.8 in 2021.
- The last three Short-Term Debt repayments figures came in at -$99752.8 (Q4 2021), -$102015.2 (Q3 2021), and -$97713.4 (Q4 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 102,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -482,347.21 |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -99,752.78 |
| Dec 31, 2021 | -99,752.78 |
| Sep 30, 2021 | -102,015.17 |
| Sep 30, 2021 | -102,015.17 |
| Dec 31, 2020 | -97,713.37 |
| Dec 31, 2020 | -97,713.37 |
| Sep 30, 2020 | -96,787.71 |
| Sep 30, 2020 | -96,787.71 |
| Dec 31, 2019 | -65,571.97 |
| Dec 31, 2019 | -65,571.97 |
| Sep 30, 2019 | -62,895.93 |
| Sep 30, 2019 | -62,895.93 |